I

IBEX

Biotech company: antibodies and gene therapy

Outbound & Inbound Specialist

Full-TimeUpdated on 10/15/2026Deadline 3/31/27
PKR85k/mo
Entry
Karachi, Karachi City, Sindh, Pakistan
In Person
Customer Experience & SupportCustomer Support

About the job

Requirements
  • O'Levels/Matriculation or above.
  • Excellent written and verbal English communication.
  • Availability to work five days a week, nine hours per day.
  • Must be at least 18 years old and hold a valid CNIC.
Responsibilities
  • Make outbound calls to patients to generate interest in vaccination trials.
  • Authenticate data collection forms and surveys.
  • Ensure all customer relationship management systems are updated with accurate information and notes.
  • Clearly communicate information to patients and doctors over the phone regarding the study.
  • Ensure compliance with all company policies, procedures, and practices.

About the company

Ibex Biosciences focuses on discovering, validating, and producing biotechnology solutions for health and ecological challenges. Its product portfolio includes therapeutic antibodies, gene therapy, and stem cell programs, as well as diagnostic antibodies for Immunohistochemistry (IHC) to improve biopsy accuracy. The company advances its products by conducting exploratory R&D on projects that may not yet be validated in public research, then develops and commercializes these technologies through licensing, partnerships, and direct sales to healthcare and research institutions. A key differentiator is Ibex’s diversified, internally driven pipeline and its mix of therapeutics and diagnostics, alongside active engagement in grant funding and patenting. The company’s goal is to bring proprietary biotech innovations to market to enhance patient outcomes and health-related research, addressing significant cancer-related and other health challenges.

Company Size

1-10

Company Stage

Early VC

Total Funding

$4.2M

Headquarters

North Bethesda, Maryland

Founded

2015

Get referred to IBEX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ibex keeps an open 506(c) offering, signaling active capital formation in 2026.
  • The 2022 CD147 patent supports oncology and inflammation licensing conversations.
  • Anti-MIF VHH development continues, with animal-model testing already disclosed.

What critics are saying

  • Ibex has no disclosed commercial products, leaving revenue dependent on financing.
  • The open Regulation D offering implies dilution risk and financing pressure through 2026.
  • Without clinical validation, the company risks becoming a perpetual patent shop.

What makes IBEX unique

  • North Bethesda-based Ibex Biosciences focuses on antibody, gene-therapy, and stem-cell programs.
  • Its 2026 pipeline spans CD147 antibodies, anti-MIF VHHs, and PCBP1 stem-cell methods.
  • Ibex still controls early patentable assets, including 2022 CD147 publication.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Ibex Innovations
Mar 12th, 2025
IBEX Completes £2m Fundraise for Osteoporosis

IBEX has successfully completed a £2 million funding round to advance its mission of using X-ray technology to diagnose osteoporosis early. The company aims to shift from reactive to proactive treatment of this silent disease. With partnerships established with X-ray and mammography OEMs in 2024, IBEX plans to deploy its technology in clinical settings by 2025, demonstrating cost savings for the NHS.

Globes
Feb 8th, 2022
Gauzy acquires Vision Systems

Israeli light control nanotech and smart glass company Gauzy has announced that it has acquired French company Vision Systems, which develops ADAS (Advanced Driver Assistance System) and shading solutions for the aeronautic, land transport, and marine industries.